M. Dowty

发表

Possible Mechanisms of DNA Uptake in Skeletal Muscle

J. Wolff, M. Dowty, 1994 .

Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle.

G. Repetto, J. Wolff, J. Ludtke, 1992, Journal of cell science.

Plasmid DNA entry into postmitotic nuclei of primary rat myotubes.

J. Hagstrom, J. Wolff, G. Zhang, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Approach for extrapolating in vitro metabolism data to refine bioconcentration factor estimates.

S. Dyer, A. Weisbrod, C. Cowan-Ellsberry, 2008, Chemosphere.

LC-MS/MS assay for N1-methylnicotinamide in humans, an endogenous probe for renal transporters.

A. D. Rodrigues, C. Holliman, M. Dowty, 2018, Bioanalysis.

Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance Mechanisms

M. Dowty, A. Thorarensen, C. Banfield, 2017, Drug Metabolism and Disposition.

Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

M. Dowty, B. Malhotra, Lisy Wang, 2021, Journal of clinical pharmacology.

Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences

J. D. Clark, M. Hegen, M. Dowty, 2020, Scientific Reports.

Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study

E. Peeva, M. Dowty, A. Banerjee, 2020, Clinical and translational science.

Use of Animal Models for Projection of Clinical Drug–Drug Interactions for Therapeutic Proteins

M. Dowty, E. Kraynov, 2013 .

A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a 14C‐Microtracer Approach

M. Dowty, S. Danto, J. Brodfuehrer, 2022, Clinical pharmacology in drug development.

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis

K. Page, E. Peeva, M. Dowty, 2018, Journal of clinical pharmacology.

Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.

J. Bauman, J. D. Clark, M. Hegen, 2016, ACS chemical biology.

The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.

J. D. Clark, J. Telliez, M. Dowty, 2016, Clinical and experimental rheumatology.

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition

M. Hegen, J. Telliez, M. Dowty, 2019, Pharmacology research & perspectives.

Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.

S. Wright, J. D. Clark, M. Hegen, 2020, Journal of medicinal chemistry.

Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.

R. Walsky, M. Dowty, S. Krishnaswami, 2012, British journal of clinical pharmacology.

Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients

T. Nicholas, M. Dowty, C. Banfield, 2022, Clinical pharmacology in drug development.

544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)

E. Peeva, B. King, M. Dowty, 2019, Journal of Investigative Dermatology.

Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.

Mark J. Mitton-Fry, J. D. Clark, M. Hegen, 2018, Journal of medicinal chemistry.

How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential

Steven W. Martin, M. Dowty, E. Kraynov, 2011, Drug Metabolism and Disposition.

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib

M. Dowty, S. Krishnaswami, Susanna Tse, 2020, Journal of clinical pharmacology.

The Next Generation of MMP Inhibitors: Design and Synthesis

M. Dowty, M. Natchus, B. Barnett, 1999, Annals of the New York Academy of Sciences.

Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).

D. Rohrer, C. Carron, C. Wegner, 2010, ACS medicinal chemistry letters.

The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans

G. S. Walker, C. Prakash, G. Chan, 2014, Drug Metabolism and Disposition.

DMD054940 759..773

G. S. Walker, C. Prakash, G. Chan, 2014 .

OP0147 Lack of Differentiation of Janus Kinase Inhibitors in Rheumatoid Arthritis Based on Janus Kinase Pharmacology and Clinically Meaningful Concentrations

J. Telliez, M. Dowty, J. Jussif, 2014 .

Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.

J. D. Clark, M. Hegen, Betsy S. Pierce, 2020, Bioorganic & medicinal chemistry.

The Next Generation of MMP Inhibitors: Design and Synthesis

M. Dowty, M. Natchus, B. Barnett, 1999, Annals of the New York Academy of Sciences.

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

John J. O’Shea, Richard D. Head, Massimo Gadina, 2011, The Journal of Immunology.

Small-Molecule Melanin-Concentrating Hormone-1 Receptor Antagonists Require Brain Penetration for Inhibition of Food Intake and Reduction in Body Weight

D. Clegg, M. Dowty, S. Benoit, 2008, Journal of Pharmacology and Experimental Therapeutics.

Animal Models for Evaluation of Drug-Drug Interaction Potential of Biotherapeutics

M. Dowty, E. Kraynov, O. Fahmi, 2012 .

Transport of Thyrotropin Releasing Hormone in Rabbit Buccal Mucosa in Vitro

J. Robinson, M. Dowty, B. Irons, 1992, Pharmaceutical Research.

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

D. Morris, J. Hirsch, S. Ramaiah, 2010, Journal of Inflammation.

A holistic strategy for characterizing the safety of metabolites through drug discovery and development.

Don Walker, Joe Brady, Deepak Dalvie, 2009, Chemical research in toxicology.

Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.

J. Bauman, J. Telliez, J. Chrencik, 2018, Journal of medicinal chemistry.

Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).

Li Xing, Eddine Saiah, David Lin, 2018, Journal of medicinal chemistry.

Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis

M. Dowty, Sarbani Ghosh, Martin E Dowty, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.

M. Hegen, J. Telliez, J. Chrencik, 2017, Journal of medicinal chemistry.

Effect of extracellular pH on cytoplasmic pH and mechanism of pH regulation in cultured bovine corneal endothelium : possible importance in drug transport studies

P. Braquet, M. Dowty, 1991 .

Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers

A. D. Rodrigues, M. Dowty, Cheng Chang, 2022, Clinical pharmacology and therapeutics.

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

M. Dowty, M. O’Gorman, B. Malhotra, 2021, Journal of clinical pharmacology.

Running title ( 56 / 60 characters including spaces ) : Preclinical to clinical translation of tofacitinib in RA

M. Dowty, Sarbani Ghosh, S. Krishnaswami, 2013 .

Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.

E. Peeva, B. King, M. Dowty, 2021, The Journal of allergy and clinical immunology.

Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.

M. Dowty, M. Natchus, M G Natchus, 2000, Journal of medicinal chemistry.

Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies

Denise M O'Hara, R. Polzer, M. Dowty, 2016, mAbs.

Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective

K. Venkatakrishnan, N. Hariparsad, J. Bolleddula, 2021, Clinical pharmacology and therapeutics.

Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals

H. Valdez, M. Dowty, M. O’Gorman, 2022, European Journal of Drug Metabolism and Pharmacokinetics.

P190 - The effect of CYP2C9 and CYP2C19 genotype on the pharmacokinetics of PF 04965842, A JAK1 inhibitor in clinical development

J. Bauman, M. Dowty, T. Goosen, 2020 .

The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans

G. S. Walker, J. Bauman, J. Telliez, 2022, Drug Metabolism and Disposition.

15433 Assessment of cytochrome P450 3A inhibition and induction of abrocitinib: Midazolam drug-drug interaction (DDI) study and oral contraceptive DDI study

G. Chan, M. Dowty, M. O’Gorman, 2020 .

Discovery of orally bioavailable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents.

Julie A Farmer, M. Dowty, C. Obringer, 2008, Journal of medicinal chemistry.

Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2

M. Dowty, Haihong Shi, S. Krishnaswami, 2014, Clinical pharmacology in drug development.

Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic approach.

A. Mazur, M. Dowty, C. Obringer, 2006, Journal of medicinal chemistry.

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

J. O’Shea, Masao Tanaka, R. Head, 2011, The Journal of Immunology.

Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.

T. Baker, M. Dowty, M. Natchus, 2000, Journal of medicinal chemistry.

Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as Probes

Robert M. Wolk, M. Dowty, A. Płotka, 2023, Journal of clinical pharmacology.

The efficacy and cardiac evaluation of aminomethyl tetrahydronaphthalene ketopiperazines: a novel class of potent MCH-R1 antagonists.

M. Dowty, O. Reizes, C. Obringer, 2007, Bioorganic & medicinal chemistry.

Novel pyrazolopiperazinone- and pyrrolopiperazinone-based MCH-R1 antagonists.

M. Dowty, O. Reizes, C. Obringer, 2007, Bioorganic & medicinal chemistry letters.

Aminomethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists--Increasing selectivity over hERG.

M. Dowty, O. Reizes, C. Obringer, 2007, Bioorganic & medicinal chemistry letters.